Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC Phase IIb study in amyotrophic lateral sclerosis
2022-002185-32Phase 2Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing PrimeC with Placebo (2 arms). Primary endpoint: Primary safety and tolerability endpoints. Started Aug 2022; status: completed.
02
Drugs
PrimeC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2022-002185-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002185-32.